Anzeige
Meldung des Tages: Das „Next Butte?“-Setup in Montana - und es ist noch immer eine $15M-Story

Citius Pharmaceuticals News

Aktie
WKN:  A40MD0 ISIN:  US17322U3068 US-Symbol:  CTXR Branche:  Pharmazeutika Land:  USA
0,7635 $
+0,0137 $
+1,83%
0,6574 € 20:39:42 Uhr
Depot/Watchlist
Marktkapitalisierung *
5,52 Mio. €
Streubesitz
76,16%
KGV
-
Index-Zuordnung
-

Citius Pharmaceuticals News

10.03.26 - PR Newswire
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory ...
24.02.26 - PR Newswire
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program PR Newswire
13.02.26 - PR Newswire
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire
13.02.26 - PR Newswire
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire
11.02.26 - PR Newswire
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar PR Newswire
23.12.25 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire
23.12.25 - PR Newswire
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire
09.12.25 - PR Newswire
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-​The-Market Under Nasdaq Rules PR Newswire
04.12.25 - PR Newswire
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim PR Newswire
01.12.25 - PR Newswire
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) PR Newswire
21.11.25 - PR Newswire
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration PR Newswire
21.10.25 - PR Newswire
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
21.10.25 - PR Newswire
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
20.10.25 - PR Newswire
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch PR Newswire
17.10.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR Newswire
16.10.25 - PR Newswire
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ PR Newswire
10.09.25 - PR Newswire
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
09.09.25 - PR Newswire
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
22.08.25 - PR Newswire
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch PR Newswire
12.08.25 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update PR Newswire

Newssuche

Videos

newspaper
19:40 Uhr -3,14%
Technical Trading: Gold Long nach Absturz
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »